Clinical trial condition

PD-1

Explore clinical trials studying PD-1. Study availability and eligibility vary by location and protocol.

16 public trials 9 recruiting studies

Refine in advanced search Browse all conditions

PD-1 trial results

Recruiting

Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors

NCT04615988

Conditions: Avitaminosis, Cancer, Deficiency Diseases, +9 more
Locations: Mount Sinai Hospital /Tisch Cancer Cancer/Ruttenberg Treatment Center New York, United States

View Trial Details

Recruiting

Study on the Safety and Tolerability of PD-1 Knockout Tumor-infiltrating T Cells (TILs) in the Treatment of Advanced Colorectal Cancer

NCT07035002

Conditions: Colonic Diseases, Colorectal Cancer (CRC), Colorectal Neoplasms, +11 more
Locations: Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, None Selected, China

View Trial Details

Recruiting

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.

NCT06635954

Conditions: Cancer, Immune Checkpoint Therapy, Immunotherapy, +3 more
Locations: Eastern Connecticut Hematology and Oncology Norwich, Connecticut, United States

Cancer Center of Middle Georgia Dublin, Georgia, United States

Carolina Blood and Cancer Care Associates Rock Hill, South Carolina, United States

View Trial Details

Recruiting

Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients

NCT04840355

Conditions: Immune Related Adverse Events, PD-1
Locations: Cancer Hospital Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China

View Trial Details

Recruiting

HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC

NCT06632093

Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatic Arterial Infusion Chemotherapy, +3 more
Locations: The first hospital of China medical university Shenyang, Liaoning, China

View Trial Details

Recruiting

Neoadjuvant Tirellizumab Combined With Chemotherapy for Early Oral Squamous Cell Carcinoma(HNC-SYSU-004)

NCT06130332

Conditions: Head and Neck Neoplasms, Mouth Diseases, Mouth Neoplasms, +5 more
Locations: Sun yat-sen memorial hospital Guangzhou, Guangdong, China

View Trial Details

Recruiting

4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC

NCT05980702

Conditions: Carcinoma, Carcinoma, Squamous Cell, HNSCC, +11 more
Locations: Sun yat-sen memorial hospital Guangzhou, Guangdong, China

View Trial Details

Recruiting

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy

NCT05980715

Conditions: Carcinoma, Carcinoma, Squamous Cell, HNSCC, +8 more
Locations: Sun yat-sen memorial hospital Guangzhou, Guangdong, China

View Trial Details

Recruiting

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

NCT04778956

Conditions: Carcinoma, Disease Attributes, Head and Neck Neoplasms, +17 more
Locations: Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China

The First Affiliated Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China

Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China

The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou, Guangdong, China

View Trial Details

Not Yet Recruiting

A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma

NCT07131501

Conditions: Adenocarcinoma, CTLA-4, Carcinoma, +14 more
Locations: The First Affiliated Hospital with Nanjing Medical University Nanjing, Jiangsu, China

View Trial Details

PD-1

PD-1 trial results

Related conditions